Nasdaq ardx.

ARDX STOCK Price - Ardelyx Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...Complete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis.ARDX Stock 12 Months Forecast. $9.92. (177.48% Upside) Based on 7 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $9.92 with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 177.48% change from the last price of $3.58.

Mar 6, 2023 · On March 02, Ardelyx ( NASDAQ: ARDX ), now nearly a $800 million cap biopharmaceutical company reported 2022 financial results and provided a business update. Since the initial coverage, shares ... Ardelyx, Inc. Common Stock (ARDX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Oct 9, 2023 · According to Seeking Alpha data, Ardelyx's market cap of $864.92M shows decent market confidence, especially with its robust revenue growth forecasts: 2023 at $100.6M, and 2024 at $175.84M ...

WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ...

ARDX Stock 12 Months Forecast. $9.92. (177.48% Upside) Based on 7 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $9.92 with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 177.48% change from the last price of $3.58.WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, …Factors of Influence in 2019, Key Indicators and Opportunity within Cousins Properties, Versum Materials, Meritor, Ardelyx, Molecular Templates, and Talend S.A — New Research Emphasizes Economic ...Ardelyx Inc (NASDAQ:ARDX)’s Major holders. Ardelyx Inc insiders own 1.74% of total outstanding shares while institutional holders control 56.10%, with the float percentage being 57.09%. State Street Corporation is the largest shareholder of the company, while 176 institutions own stock in it. As of Jun 29, 2023, the company held …ARDX STOCK Price - Ardelyx Inc NASDAQ USA Technical Analysis, Forecast, Important Levels, Latest News, Interactive Charts.

WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...

Market Activity. Funds + ETFs. After-Hours Quotes. News + Insights. P/E & PEG Ratios. . Here you can find up-to-the-minute news and analysis of the company that you are researching for potential ...

Dec 3, 2023 · Ardelyx (NASDAQ:ARDX – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report released on Friday, Benzinga reports. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. Wedbush’s price objective would suggest a potential upside of 89.08% from the company’s previous close. Several other ... Ardelyx (NASDAQ:ARDX) is scheduled to announce Q4 earnings results on Thursday, March 2nd, after market close.The consensus EPS Estimate is -$0.02 and the consensus Revenue Estimate is $23.18M (vs ...Ardelyx, Inc. (NASDAQ:ARDX) BioNTech SE (NASDAQ:BNTX) Globus Medical, Inc. (NYSE:GMED) GW Pharmaceuticals plc (NASDAQ:GWPH) Medpace Holdings, Inc. (NASDAQ:MEDP) ... Qorvo (NASDAQ:QRVO) said the ...The stock of Ardelyx Inc (NASDAQ: ARDX) has decreased by 0.00 when compared to last closing price of 3.56.Despite this, the company has seen a loss of -11.44% in its stock price over the last five trading days. The Motley Fool reported 2023-10-31 that Ardelyx delivered a surprise profit thanks to strong sales of Ibsrela, its first FDA-approved ...Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.

3 Penny Stocks to Buy and Hold for the Next 10 Years. 1 month ago. Simply Wall St. 1 week ago. Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, …Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, surging 15% in the last week alone The latest price target for Ardelyx ( NASDAQ: ARDX) was reported by HC Wainwright & Co. on Wednesday, November 1, 2023. The analyst firm set a price target for 11.00 expecting ARDX to rise to ...Ardelyx, Inc. ( NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations for tenapanor for hyperphosphatemia at the …Ardelyx Inc (NASDAQ:ARDX) trade information. Upright in the red during last session for losing -0.39%, in the last five days ARDX remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $3.86 price level, adding 6.76% to its value on the day.Shares of Ardelyx, Inc. (NASDAQ:ARDX) got a boost, shooting 37% to $1.6750 after the company announced the FDA Advisory Committee voted 9-to-4 that the benefits of XPHOZAH outweigh its risks for ...

Dec 13, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ...

Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.WALTHAM, Mass., Oct. 20, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class ...Ardelyx (NASDAQ:ARDX) shareholders have earned a 226% return over the last year. Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality ...WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Nov 24, 2023 · Who is on Ardelyx's Insider Roster? The list of insiders at Ardelyx includes David M. Mott, David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell, and Susan Rodriguez. Learn more on insiders at ARDX. Ardelyx. 03 Jun, 2022, 08:00 ET. WALTHAM, Mass., June 3, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX ), a biopharmaceutical company founded with a mission to discover, develop and ...WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Join the Nasdaq+ community for more personalized data, exclusive content, and market analysis. Try it today for $4.99/month. Subscribe Now.Oct 9, 2023 · According to Seeking Alpha data, Ardelyx's market cap of $864.92M shows decent market confidence, especially with its robust revenue growth forecasts: 2023 at $100.6M, and 2024 at $175.84M ...

Nov 24, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. After registering a -0.23% downside in the last session, Ardelyx Inc (ARDX) has traded red over the past five days. The stock hit a weekly high of 4.49 this Wednesday, 11/22/23, dropping -0.23% in its intraday price action. The 5-day price performance for the stock is 11.37%, and 14.02% over 30 days.

Ardelyx Inc (NASDAQ:ARDX) is the most popular stock in this table. On the other hand Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS ) is the least popular one with only 8 bullish hedge fund positions.

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...Ardelyx has generated ($0.12) earnings per share over the last year ( ($0.12) diluted earnings per share). Earnings for Ardelyx are expected to grow in the coming year, from ($0.31) to ($0.24) per share. Ardelyx has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 ...Nov 20, 2023 · Ulysses Erickson. November 20, 2023. In the latest trading session, 1.04 million Ardelyx Inc (NASDAQ:ARDX) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $4.30 changed hands at -$0.03 or -0.69% at last look, the market valuation stands at $998.20M. ARDX’s current price is a ... Sep 20, 2021 · Sep 20, 2021 6:14AM EDT. Every investor in Ardelyx, Inc. (NASDAQ:ARDX) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we ... Find the latest historical data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.AzurRx, Inc. (NASDAQ:AZRX) said due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9.09 million ...WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs.Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of …Ardelyx (NASDAQ: ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for …

Ardelyx Inc (NASDAQ:ARDX) trade information. Instantly ARDX has showed a red trend with a performance of -1.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.49 on Monday, 11/27/23 increased the stock’s daily price by 4.01%.EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.10. 3 Months Ago. -$0.11. Ardelyx Inc. analyst estimates, including ARDX earnings per share estimates and analyst recommendations.Dec 1, 2023 · Ardelyx Inc (NASDAQ:ARDX)’s Major holders Ardelyx Inc insiders own 1.74% of total outstanding shares while institutional holders control 56.10%, with the float percentage being 57.09%. State Street Corporation is the largest shareholder of the company, while 176 institutions own stock in it. Instagram:https://instagram. reddit pot stocksshare price baiduholidays stock marketwhat is ark7 WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...Shares of the small-cap biotech Ardelyx ( ARDX 1.62%) fell by a whopping 73.2% in pre-market action Tuesday morning. The drugmaker's stock is tanking today in response to a July 13 letter from the ... apgaxie stock Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. nextera energy stock forecast Shares of Ardelyx (NASDAQ: ARDX) were up 13.2% as of 2:30 p.m. ET Wednesday after the U.S. Food and Drug Administration (FDA) approved its first-in-class chronic kidney disease drug. In a press ...Hycroft Mining Holding Corporation Class A Common Stock (HYMC) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.